Literature DB >> 15954894

Lipoxin A4 inhibits TNF-alpha-induced production of interleukins and proliferation of rat mesangial cells.

Sheng-Hua Wu1, Chao Lu, Ling Dong, Guo-Ping Zhou, Zha-Guang He, Zi-Qing Chen.   

Abstract

BACKGROUND: Studies have shown that lipoxin A(4) (LXA(4)) and its analogues inhibited proliferation of glomerular mesangial cells induced by leukotriene D(4) (LTD(4)) or platelet-derived growth factor (PDGF), reduced the production of proinflammatory cytokines such as interleukin (IL)-1beta and IL-6 in renal tissue of ischemic injury. In the present studies, we examine whether LXA(4) have inhibitory effects on tumor necrosis factor-alpha (TNF-alpha)-induced productions of IL-1beta and IL-6 and proliferation of glomerular mesangial cells of rat, and explore the molecular mechanisms of signal pathway of LXA(4).
METHODS: Cultured glomerular mesangial cells were treated with TNF-alpha (10 ng/mL), with or without preincubation with LXA(4) at the different concentrations. Cell proliferation was assessed by [(3)H]-thymidine incorporation. Proteins of IL-1beta and IL-6 in supernatant were analyzed by enzyme-linked immunosorbent assay (ELISA). Expressions of mRNA of IL-1beta and IL-6 were determined by real-time polymerase chain reaction (PCR) and cyclin E by reverse transcription (RT)-PCR. Proteins of cyclin E, threonine phosphorylated Akt(1) at 308 site (Thr(308)) and p27(kip1) were analyzed by Western blotting studies. Activities of signal transducers and activators of transcription-3 (STAT(3)), nuclear factor-kappaB (NF-kappaB) were determined by electrophroretic mobility shift assay (EMSA). Expression of Src homology (SH) 2-containing protein-tyrosine phosphatase (SHP-2) was assessed by immunoprecipitation and immunoblotting.
RESULTS: TNF-alpha-stimulated proliferation, release of proteins and expressions of mRNA of IL-1beta and IL-6 in mesangial cells were inhibited by LXA(4) in a dose-dependent manner. The marked increments in mRNA expression and protein synthesis of cyclin E induced by TNF-alpha in parallel with proliferation of mesangial cells were down-regulated by LXA(4). LXA(4) antagonized the phosphorylation of SHP-2 and activity of NF-kappaB induced by TNF-alpha. Pretreatment of the cells with NF-kappaB inhibitor pyrrolidine dithio-carbamate (PDTC) blocked the productions of IL-1beta, IL-6, and activation of NF-kappaB induced by TNF-alpha. Stimulation of mesangial cells with TNF-alpha resulted in enhanced DNA-binding activity of STAT(3). This increment was inhibited by LXA(4) in a dose-dependent manner. Threonine phosphorylated Akt(1) protein at 308 site stimulated by TNF-alpha was reduced by LXA(4.) TNF-alpha-induced decrement in expression of p27(kip1) protein was ameliorated by LXA(4) in a dose-dependent manner.
CONCLUSION: TNF-alpha-induced proliferation and increment of cyclin E of rat mesangial cells can be inhibited by LXA(4), and these inhibitory effects might be through the mechanisms of STAT(3) and Akt(1)/p27(kip1) pathway-dependent signal transduction. LXA(4) also antagonized TNF-alpha-stimulated IL-1beta and IL-6 synthesis, and these antagonisms were related to SHP-2 and NF-kappaB pathway-dependent signal transduction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15954894     DOI: 10.1111/j.1523-1755.2005.00379.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  17 in total

1.  Impaired phagocytic mechanism in annexin 1 null macrophages.

Authors:  Simon Yona; Sigrid E M Heinsbroek; Leanne Peiser; Siamon Gordon; Mauro Perretti; Roderick J Flower
Journal:  Br J Pharmacol       Date:  2006-04-24       Impact factor: 8.739

Review 2.  Expression and signaling of formyl-peptide receptors in the brain.

Authors:  Fabio Cattaneo; Germano Guerra; Rosario Ammendola
Journal:  Neurochem Res       Date:  2010-11-02       Impact factor: 3.996

Review 3.  Molecular biology for formyl peptide receptors in human diseases.

Authors:  Yongsheng Li; Duyun Ye
Journal:  J Mol Med (Berl)       Date:  2013-02-13       Impact factor: 4.599

4.  Lipoxin A4-Mediated p38 MAPK Signaling Pathway Protects Mice Against Collagen-Induced Arthritis.

Authors:  Jinyu Li; Qi Sun; Chenying Zheng; Chunxiao Bai; Chuyin Liu; Xueqian Zhao; Peiying Deng; Limin Chai; Yusong Jia
Journal:  Biochem Genet       Date:  2020-11-22       Impact factor: 1.890

5.  Hepatitis B virus X protein up-regulates tumor necrosis factor-α expression in cultured mesangial cells via ERKs and NF-κB pathways.

Authors:  Hong-Zhu Lu; Jian-Hua Zhou
Journal:  Asian Pac J Trop Biomed       Date:  2013-03

6.  Lipoxin A4 inhibits lipopolysaccharide-induced production of inflammatory cytokines in keratinocytes by up-regulating SOCS2 and down-regulating TRAF6.

Authors:  Feng Hu; Ai-Ping Feng; Xin-Xin Liu; Song Zhang; Jun-Tao Xu; Xin Wang; Xue-Lian Zhong; Meng-Wen He; Hong-Xiang Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-06-14

Review 7.  Lipoxins: resolutionary road.

Authors:  Paola Maderna; Catherine Godson
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

Review 8.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

9.  Elevated expressions of 15-lipoxygenase and lipoxin A4 in children with acute poststreptococcal glomerulonephritis.

Authors:  Sheng-Hua Wu; Pei-Yuan Liao; Pei-Ling Yin; Yong-Mei Zhang; Ling Dong
Journal:  Am J Pathol       Date:  2008-12-18       Impact factor: 4.307

10.  ATL-1, an analogue of aspirin-triggered lipoxin A4, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor.

Authors:  P F T Cezar-de-Mello; A M Vieira; V Nascimento-Silva; C G Villela; C Barja-Fidalgo; I M Fierro
Journal:  Br J Pharmacol       Date:  2008-01-14       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.